Compare GSK plc (GSK) vs Zillow Group Inc Class A (ZG) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Zillow Group (ZG) trades at $33.80, up 6.29% today, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company reported revenue of $2.58 billion in 2025, turning profitable with net income of $23 million after years of losses. Recent earnings have beaten expectations in two of the last three quarters, though the stock faces headwinds from multiple securities fraud lawsuits filed in July 2026 alleging anticompetitive practices.

The investment outlook is cautiously optimistic given analyst consensus with a $57.80 price target and 51% buy ratings, but legal risks and high P/E of 134.94 pose significant challenges. Upside depends on sustained revenue growth and resolution of litigation, while downside risks include prolonged legal battles and competitive pressures in the housing market.